Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study

Diabetologia ◽

10.1007/s00125-020-05200-w ◽

2020 ◽

Vol 63 (9) ◽

pp. 1808-1821 ◽

Author(s):

Michelle Rosenzwajg ◽

Randa Salet ◽

Roberta Lorenzon ◽

Nicolas Tchitchek ◽

Alexandra Roux ◽

...

Keyword(s):

Type 1 Diabetes ◽

Phase I ◽

Low Dose ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Low-Dose Interleukin 2 in Children with Recently Diagnosed Type 1 Diabetes: A Phase 1/2 Randomised, Double-Blind, Placebo-Controlled Dose Finding Study

SSRN Electronic Journal ◽

10.2139/ssrn.3384899 ◽

2019 ◽

Author(s):

Randa Salet ◽

Michelle Rosenzwajg ◽

Roberta Lorenzon ◽

Alexandra Roux ◽

Jean Claude Carel ◽

...

Keyword(s):

Type 1 Diabetes ◽

Low Dose ◽

Phase 1 ◽

Interleukin 2 ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Deramciclane in the treatment of patients with generalised anxiety disorder: A randomised, double-blind, placebo-controlled, dose-finding study

European Neuropsychopharmacology ◽

10.1016/s0924-977x(01)80407-7 ◽

2001 ◽

Vol 11 ◽

pp. S301-S302 ◽

Author(s):

H. Naukkarinen

Keyword(s):

Anxiety Disorder ◽

Dose Finding ◽

Generalised Anxiety Disorder ◽

Double Blind ◽

Double Blind Placebo ◽

Finding Study ◽

Dose Finding Study

Download Full-text

A 9-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of Modafinil as Treatment for Adults With ADHD

Journal of Attention Disorders ◽

10.1177/1087054712441969 ◽

2012 ◽

Vol 18 (2) ◽

pp. 133-144 ◽

Author(s):

Valerie K. Arnold ◽

David Feifel ◽

Craig Q. Earl ◽

Ronghua Yang ◽

Lenard A. Adler

Keyword(s):

Dose Finding ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study

LUTS Lower Urinary Tract Symptoms ◽

10.1111/luts.12053 ◽

2014 ◽

Vol 7 (2) ◽

pp. 84-92 ◽

Author(s):

Osamu YAMAGUCHI ◽

Eiji MARUI ◽

Yasuhiko IGAWA ◽

Masayuki TAKEDA ◽

Osamu NISHIZAWA ◽

...

Keyword(s):

Overactive Bladder ◽

Japanese Patients ◽

Dose Finding ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Adrenoceptor Agonist ◽

Finding Study ◽

Dose Finding Study

Download Full-text

The effect on bone mass and bone markers of different doses of ibandronate — A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo-controlled dose-finding study

Osteoporosis International ◽

10.1007/bf02500731 ◽

1996 ◽

Vol 6 (S1) ◽

pp. 301-301 ◽

Author(s):

P. Ravn ◽

B. Clemmesen ◽

B. J. Riis ◽

C. Christiansen

Keyword(s):

Bone Mass ◽

Postmenopausal Osteoporosis ◽

Bone Markers ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Prevention And Treatment ◽

Finding Study ◽

Dose Finding Study ◽

Different Doses

Download Full-text

Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study

PLoS ONE ◽

10.1371/journal.pone.0204896 ◽

2018 ◽

Vol 13 (10) ◽

pp. e0204896 ◽

Author(s):

Tadao Akizawa ◽

Ryutaro Shimazaki ◽

Masafumi Fukagawa ◽

Keyword(s):

Secondary Hyperparathyroidism ◽

Japanese Patients ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Pranidipine, a novel calcium antagonist, once daily, for the treatment of hypertension: A multicenter, double-blind, placebo-controlled dose-finding study

Cardiovascular Drugs and Therapy ◽

10.1007/bf00051131 ◽

1996 ◽

Vol 10 (1) ◽

pp. 59-66 ◽

Author(s):

Julian Rosenthal ◽

Norbert Hittel ◽

Karl Otto Stumpe

Keyword(s):

Calcium Antagonist ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Treatment Of Hypertension ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

Pain ◽

10.1016/j.pain.2007.11.008 ◽

2008 ◽

Vol 137 (2) ◽

pp. 428-440 ◽

Author(s):

Lynn Webster ◽

Jan Peter Jansen ◽

John Peppin ◽

Ben Lasko ◽

Gordon Irving ◽

...

Keyword(s):

Cancer Pain ◽

Opioid Receptor ◽

Bowel Dysfunction ◽

Mu Opioid Receptor ◽

Dose Finding ◽

Double Blind ◽

Mu Opioid ◽

Double Blind Placebo ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70113-x ◽

2013 ◽

Vol 1 (4) ◽

pp. 295-305 ◽

Author(s):

Agnès Hartemann ◽

Gilbert Bensimon ◽

Christine A Payan ◽

Sophie Jacqueminet ◽

Olivier Bourron ◽

...

Keyword(s):

Type 1 Diabetes ◽

Low Dose ◽

Controlled Trial ◽

Phase 1 ◽

Interleukin 2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease

The International Journal of Cardiovascular Imaging ◽

10.1007/s10554-013-0253-3 ◽

2013 ◽

Vol 29 (S1) ◽

pp. 7-20 ◽

Author(s):

Masahiro Jinzaki ◽

Masaharu Hirano ◽

Kazuhiro Hara ◽

Takahiko Suzuki ◽

Akira Yamashina ◽

...

Keyword(s):

Phase Ii ◽

Cardiac Disease ◽

Dose Finding ◽

Double Blind ◽

Double Blind Placebo ◽

Short Acting ◽

Landiolol Hydrochloride ◽

Finding Study ◽

Dose Finding Study

Download Full-text